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Abstract: Antimicrobial activity is a well-known property of propolis, making it a candidate
for antimicrobial surfaces in biomedical devices. Nevertheless, large-scale use of propolis as
an anti-infective agent is limited by the heterogeneity of its chemical composition and consequent
variation in antimicrobial activity. The aim of this study was to demonstrate that the multi dynamic
extraction (M.E.D.) method produces standardized polyphenolic mixtures from poplar-type propolis,
with reproducible chemical composition and anti-microbial activity, independently from the chemical
composition of the starting raw propolis. Three raw propolis samples, from Europe, America,
and Asia, were analyzed for their polyphenol chemical composition by means of HPLC–UV and
then combined to obtain three mixtures of propolis, which werme submitted to the M.E.D. extraction
method. The chemical composition and the antimicrobial activity of M.E.D. propolis against bacteria
and fungi were determined. The three M.E.D. propolis showed similar chemical compositions
and antimicrobial activities, exhibiting no relevant differences against antibiotic-susceptible and
antibiotic-resistant strains. The batch-to-batch reproducibility of propolis extracts obtained with
the M.E.D. method encourages the design of drugs alternative to traditional antibiotics and the
development of anti-infective surface-modified biomaterials.
Keywords: multi dynamic extraction (M.E.D.) method; poplar-type propolis; standardized polyphenolic
mixture; antimicrobial activity; antibiotic-resistant bacteria; anti-infective agent; anti-infective biomaterials
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1. Introduction
Propolis is a natural resinous product, processed by bees from a range of plants for use in
construction of their hives [1,2]. Its composition varies depending on its botanical and geographical
origins [3], although the different types of propolis do have a shared chemical nature [4]. In fact,
in addition to resin (50%), wax (30%), essential oils (10%), pollen (5%), and mineral salts (2%), the main
components of propolis are polyphenols, including flavonoids, phenolic acids, and their esters [5].
The analysis of the chemical composition and biological properties of propolis, as well as its use
in drugs, foods, and cosmetics requires an extraction process so as to remove impurities and inert
materials while preserving the majority of the plant secondary metabolites, especially the polyphenol
fraction [4–6]. Until now, this has been generally achieved by extraction with solvents, in particular
with 70% ethanol. Hydro-alcoholic extraction results in wax-free tinctures containing variable amounts
of bioactive compounds, including the phenolic substances [7,8]. Nevertheless, while simple and
effective, this method suffers from some limits in application due to the potential presence of ethanol
residues in the resultant pharmaceutical products, foods, and cosmetics.
Therefore, the production of non-ethanolic propolis extracts represents an important prospect,
with progress focused on solubilization of the active molecules of propolis in aqueous or oily solvents,
as phenolic compounds were found at 10-fold lower concentrations in these conditions compared
to ethanolic extracts [9,10]. A new, patented propolis extraction method, called multi dynamic
extraction (M.E.D.), has recently been proposed [11,12]. M.E.D. allows the preparation of non-ethanolic
propolis extracts (M.E.D. extracts) with reliable polyphenolic contents, in contrast to the majority
of other extraction methods that yield a poorly replicable chemical composition. On the contrary,
M.E.D. extracts possess a standardized polyphenol composition containing 5–20% phenolic acids
and 50–80% flavonoids (20–30% flavones and flavonols, 30–50% flavanones and dihydroflavonols,
5–20% glycosilated flavonoids and terpenoids), with these extracts being rich in six active compounds,
i.e., galangin, chrysin, pinocembrin, apigenin, pinobanksin, and quercetin, with a relative concentration
of about 40% (w/w) [13]. From its composition, M.E.D. extract can be defined as a poplar-type
propolis polyphenolic mixture, rich in bioactive compounds, and highly purified from impurities and
inert materials [12].
Propolis demonstrates many healthy properties, of which the most studied is antimicrobial
activity [5,14–17], which has been described against multiple bacterial strains and fungi [18,19].
The complex mechanism by which propolis exerts its antimicrobial activity is yet to be elucidated
and could involve synergisms between different polyphenols [20]. The major problems regarding
these studies on the antimicrobial properties of propolis consist in the variation in composition of the
studied propolis extracts, which give different results in terms of antimicrobial activity and make it
impossible to compare results obtained from different propolis extracts. A further limit of the literature
data is that the chemical composition of the tested extracts is different from that of the extracts currently
used as drug, food, or cosmetics ingredients and so these results have limited practical applications.
In summary, several factors such as origin, composition, and extraction method can influence the
biological behavior of the product. On the basis of these considerations, following a request from the
European Commission about a list of propolis health claims, the opinion of the European Food Safety
Authority (EFSA) was that a cause–effect relationship cannot be established between the consumption
of propolis and the claimed effects, due to the fact that “type and content of flavonoids in propolis may vary
depending on the specific propolis raw material as well as the extraction and preparation methods”.
The aim of our study is to demonstrate the chemical and biological reproducibility of poplar-type
propolis extracts obtained using a M.E.D. method on a combination of poplar-type propolis of different
geographical origins. Thus, the chemical composition of nine hydroalcoholic propolis extracts and three
non-ethanolic M.E.D. propolis was evaluated by high-performance liquid chromatography coupled
with UV detection and mass spectrometry (HPLC–UV–MSn) and these were compared. In addition,
the antimicrobial activity was used as a validation method of the extractive process M.E.D. to show the
biological reproducibility of M.E.D. propolis.
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2. Materials and Methods
2.1. Materials
HPLC-grade water was obtained from a LC-Pak™ Millex system (Millipore Corporation, Billerica,
MA, USA). Formic acid, MS grade methanol, quercetin, apigenin, pinobaskin, crysin, pinocembrin,
and galangin were obtained from PhytoLab, Vestenbergsgreuth, Germany.
2.2. Hydroalcoholic Propolis Extract Preparation
Three poplar-type raw propolis samples were obtained from as many European regions (Italy (E1),
Spain (E2), and Turkey (E3)), three further poplar-type raw propolis samples were obtained from three
different Southern American regions (Uruguay (sA1), Mexico (sA2), and Argentina (sA3)), and the last
three poplar-type raw propolis samples were collected from distinct Asian regions (Mongolia (A1),
Kazakhstan (A2), and north China (A3)). Samples (20 mg each) were dissolved in 2 mL of 70% ethanol.
After vigorous mixing and sonication for 30 min, polyphenols were extracted at 70 ◦C in a water bath
for 2 hours under continuous mixing. After centrifugation at 10,000 RPM for 10 min, hydroalcoholic
propolis extracts were analyzed by RP-HPLC–PDA–ESI–MSn.
2.3. M.E.D. Propolis Preparation
In order to determine the chemical composition and test the antibacterial activity of M.E.D.
propolis, three mixtures (mix A, mix B, and mix C) were prepared combining a European, an American,
and an Asian poplar-type raw propolis sample (Eu + Am + As). M.E.D. propolis A, B, and C, respectively,
were obtained from each raw mixture using M.E.D. (multi dynamic extraction), as reported in [11].
In brief, raw propolis mixtures were submitted to the M.E.D. extraction process, comprising several
steps. These steps consisted of an initial aqueous extraction from dewaxed raw propolis, followed by
a series of extractions on the residue using an ethanol/water mixture, with each extraction being carried
out on the residue from the previous extraction using a higher percentage of ethanol. The combined
extracts were mixed and concentrated by distillation to a residual humidity value ranging from 15 to
20% (w/w). The concentrated extracts were then analyzed by RP-HPLC–PDA–ESI–MSn and submitted
to an antimicrobial assay.
2.4. Analyses of Hydroalcoholic Propolis Extracts and M.E.D. Propolis by RP-HPLC–PDA–ESI–MSn
The chromatographic analyses were performed by means of the RP-HPLC-PAD-ESI-MSn method,
set up by Cui-ping et al., with some modifications [21]. These were performed using an Agilent
1100 VL series mass spectrometer (Agilent Technologies, Inc., Santa Clara, CA, USA), which was
further used on-line with HPLC equipment. The electrospray interface was set in negative ionization
mode with the capillary voltage at 3500 V and a temperature source of 350 ◦C in full scan spectra
(200–2200 Da, 10 full scans/s). Nitrogen was used as a drying (9 L/min) and nebulizing gas (11 p.s.i.).
Software versions were 4.0 LC/MSD trap control 4.2 and Data Analysis 2.2 (Agilent Technologies,
Inc., Santa Clara, CA, USA). Compound separation was obtained with an analytical Synergi Fusion
RP-18 column (150_4.6 mm, 5_m), equipped with a Hypersil Gold C18 precolumn (10 _2.1 mm,
5_m), all produced by Phenomenex (Torrance, CA, USA). The mobile phase used was acidified
water, with 0.1% formic acid (eluent A) and methanol (eluent B). The run time was 110 min in total,
including the reconditioning of the column. The flow rate was maintained at 1.00 mL/min, and the
temperatures of the autosampler and column were kept at 4 and 33 ◦C. The volume of injection was
set to 5 L. The elution method is described in Table 1. Chromatograms were registered at 260 nm.
The HPLC-ESI-MSn data were collected using Xcalibur software (Xcalibur 2.0, Thermo Fisher Scientific,
Waltham, MA, USA).
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Table 1. RP-HPLC–PDA–ESI–MSn analysis elution method.
Time (min) % Eluent A % Eluent B
0 85 15
30 60 40
65 45 55
70 38 62
85 0 100
90 0 100
100 85 15
110 85 15
2.5. Antimicrobial Assays
In order to determine the inhibitory effects of M.E.D. propolis against different microorganisms,
these experiments were carried out using the broth dilution method according to the procedures of
the Clinical and Laboratory Standards Institute (CLSI), so as to determine the minimum inhibitory
concentration (MIC), defined as the lowest concentration of an antimicrobial agent that can inhibit the
growth of microorganisms.
Each dry M.E.D. propolis extract (A, B, or C) was resuspended in 50% (v/v) ethanol/water to obtain
a final concentration of 50 mg/mL. A blank sample was also prepared, without adding any extract.
Then, the three samples were serially diluted 1:2 in 50% ethanol, and 0.8 mL of each dilution were
mixed with 7.2 mL of the specific agar culture medium, previously equilibrated at 70 ◦C, to finally
cover a polyphenol concentration range between 0.007 mg/mL and 0.872 mg/mL. Once perfectly mixed
by vortexing, agar culture medium was added to each propolis extract at different concentrations
and then poured into a 6 mm Petri plate, and a cell suspension from a frozen vial was plated at
about 5 × 103 CFU/spot. As a positive control, some plates were prepared with the culture medium
containing 0.8 mL of the blank stock. The growing media and conditions were chosen according to
microorganism species (Table 2).
Table 2. The growing conditions for the microorganisms selected to test propolis antimicrobial activity.
Microbial Strain Media Conditions
S. aureus methicillin-sensitive ATCC25923
(MSSA)(L1280)
S. aureus methicillin-resistant (MRSA) (L4064)
S. aureus MSSA + glycopeptide-interMediate
resistant (GISA) (L3797)
S. aureus MRSA + GISA (L3798)
S. aureus clinda-inducible erm(A)+ (ND053410)
S. aureus community acquired USA300 MRSA
(ND054910)
S. aureus MRSA + macrolides-resistant (ND060411)
S. hominis ATCC27844 (L323)
S. epidermidis (L147; ND052110; ND051710)
S. epidermidis teicoplanin-resistant (ND042409)
S. capitis MRSA (ND021008)
S. xylosus MRSA (ND026108)
S. simulans (ND029808)
S. haemolyticus MRSA (L1730, ND040809; L1729)
E. coli hyperpermeable (G1640)
E. coli ATCC25922 (L1281)
E. coli hyperpermeable (L4242; L47)
P. aeruginosa ATCC27853 (L1367)
M. catarrhalis (L3292)
A. baumannii (L3030)
L. monocytogenes ATCC13932 (L1450)
B. cereus ATCC10702 (L85)
Mueller Hinton Agar Aerobic, 24 h, 37 ◦C
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Table 2. Cont.
Microbial Strain Media Conditions
S. pneumoniae penicillin-susceptible (L44)
S. pneumoniae penicillin-resistant (L3917)
S. pneumoniae clindamycin and erythromycin
resistant (L1542)
S. pneumoniae macrolide and erythromycin resistant
(L1402)
Todd Hewitt Agar Aerobic, 24 h, 37 ◦C
C. parapsilosis ATCC90018 (L3022)
C. parapsilosis ATCC22019 (L4119)
C. albicans ATCC24443 (L4120)
C. albicans ATCC90028 (L3023)
C. guillermondii ATCC6260 (L2065)
C. kruzei (L2880)
A. niger ATCC10535 (L53)
Sabouraud
Dextrose Agar Aerobic, 48 h, 37
◦C
G. vaginalis (L1629; L1622; L1630)
A. vaginae (ND736; ND737)
B. fragilis ATCC25285 (L1011)
L. paracasei (L1693)
L. plantarum (L19)
L. gasseri (ND787)
L. acidophilus (ND786)
C. difficile (L1365; L1366)
C. difficile ATCC17858 (L4013)
Brucella Agar with 5%
laked horse blood and 1%
hemin and vitamin K
Anaerobic, 72 h, 37 ◦C
N. gonorrhoeae (L1600; L1601; L1599)
Brucella Agar with 5%
laked horse blood, 1%
hemin and vitamin K and
1% isovitalex
Anaerobic, 72 h, 37 ◦C
C. perfrigens (L4053)
C. perfrigens ATCC13124 (L3697)
P. acnes ATCC25746 (L1016)
Brucella Agar with 5%
laked horse blood and 1%
hemin and vitamin K
Anaerobic, 48 h, 37 ◦C
A large panel of bacterial and fungal species (Table 2) were used to test the antimicrobial activity of
M.E.D. propolis, sourced from the American Type Culture Collection (ATCC) and clinical isolates (Code
L) provided by Naicos srl, Milan, Italy (IRCCS Policlinico San Donato, San Donato Milanese, Italy; Centre
Hospitalier Universitaire de Limoges, Limoges, France; International Health Management Associates, Inc.,
Shaumburg, IL, USA; Micromyx, LLC, Kalamazoo, MI, USA; Ospedale Busto Arstizio, Busto Arsizio,
Italy; MM: IRCCS Multimedica, Milan, Itay; Rockville, MD, USA; S. Raffaele Hospital, Milan, Italy).
The tested microorganisms included both drug-resistant species, showing resistance against one or more
antibiotics, and sensitive species, i.e., non-resistant (Table 7). Tables 7 and 8 present the MIC values of
selected antibiotics as reported by the literature where available, these were used as positive control.
2.6. Statistical Analysis
The values represent mean values of at least 3 replications. Data were analyzed by analysis of
variance (ANOVA) with the statistical package GraphPad PRISM v 6.0 (2015) (GraphPad Software Inc.,
San Jose, CA, USA). Means were separated with the Tukey’s HSD method.
3. Results
3.1. RP-HPLC–PDA–ESI–MSn Analyses of Hydroalcoholic Propolis Extracts
Raw poplar-type propolis materials, obtained from three European regions (Eu1, Eu2, Eu3), three
Southern American regions (Am1, Am2, Am3), and three Asian regions (As1, As2, As3) were submitted
to hydroalcoholic extraction. The extracts were analyzed by means of RP-HPLC–PDA–ESI–MSn.
The main flavonoid species, flavonols (galangin, quercetin), flavones (chrysin, apigenin), and flavonones
(pinocembrin, pinobanksin), were identified on the basis of their UV and mass spectra, checking the
molecular ion and fragment ions against the fragmentation patterns of standard molecules (Table 3) [12].
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Table 3. Chromatographic and spectral properties of polyphenol compounds detected in propolis samples.
Peak number RT(min)
UV
absorption
(λmax)
m/z
[M-H]
Fragments
(m/z) Proposed Structure
1 31.8 256 301 151, 179, 257, 273 Quercetin
2 35.2 325 271 151, 165, 225, 253 Pinobaskin
3 35.5 267, 338 269 117, 149, 225 Apigenin
4 44.7 270 253 209 Chrysin
5 45.5 290 255 151, 187, 213 Pinocembri
6 46.2 261, 351 269 227 Galangin
After the initial identification of quercetin, apigenin, pinobaskin, chrysin, pinocembrin, and galangin,
they were determined by an on-line HPLC–UV according to methods previously described (Table 4).
The results (Table 4) showed that while the total polyphenol contents of the Asian hydroalcoholic
propolis extracts were similar (mean value: 46.3% w/w, standard deviation: 0.8), the total polyphenol
content of the American propolis samples ranged from 37.8 to 59.3 (mean value: 50.1%, standard
deviation: 11.1), as was the case for the total polyphenol contents of the European propolis samples,
which ranged from 38.2 to 42.6 (mean value: 40.6%, standard deviation 2.2).
As far as the relative percentage of each main flavonoid compound is concerned, the analysis
of variance (ANOVA) was used to evaluate whether the concentration of each compound was
statistically different between the hydroalcoholic propolis extracts, considering their different origins.
The results, reported in Table 5, showed that the relative percentages of the polyphenols were often
statistically different, confirming that the high variability of propolis raw materials of different
origin leads to propolis extracts with different compositions when using common extraction methods
(i.e., hydroalcoholic extraction) (Figure 1).
Table 4. Relative percentage (% w/w) of the specific polyphenols occurring in the nine hydroalcoholic
propolis extracts of different geographical origins, determined by HPLC-UV.
Polyphenols Eu1 Eu2 Eu3
1-Quercetin 1.4 ± 0.6 0.8 ± 0.2 0.7 ± 0.4
2-Pinobanksin 1.5 ± 0.1 1.0 ± 0.2 1.5 ± 0.3
3-Apigenin 1.6 ± 0.3 1.1 ± 0.3 1.2 ± 0.3
4-Chrysin 18.3 ± 0.3 21.4 ± 0.2 24.1 ± 0.4
5-Pinocembrin 2.8 ± 0.3 4.8 ± 0.1 3.1 ± 0.2
6-Galangin 12.6 ± 0.1 12.0 ± 0.1 12.0 ± 0.2
Sum of percentages 38.2 41.1 42.6
- Am1 Am2 Am3
1-Quercetin 0.5 ± 0-6 0.5 ± 0.1 0.9 ± 0.5
2-Pinobanksin 1.0 ± 0.2 0.9 ± 0.2 3.0 ± 0.8
3-Apigenin 1.5 ± 0.9 0.9 ± 0.3 3.5 ± 1.2
4-Chrysin 30.3 ± 3.3 22.2 ± 1.1 28.6 ± 0.6
5-Pinocembrin 4.4 ± 0.4 1.8 ± 0.3 13.9 ± 1.1
6-Galangin 15.4 ± 0.6 11.5 ± 0.4 9.4 ± 1.3
Sum of percentages 53.1 37.8 59.3
- As1 As2 As3
1-Quercetin 0.4 ± 0.4 0.4 ± 0.5 0.9 ± 0.4
2-Pinobanksin 1.0 ± 0.2 1.8 ± 0.4 10.0 ± 2.0
3-Apigenin 2.2 ± 0.8 2.0 ± 1.7 1.2 ± 0.1
4-Chrysin 25.0 ± 2.5 24.4 ± 0.8 19.6 ± 1.4
5-Pinocembrin 2.0 ± 0.1 2.4 ± 0.1 1.7 ± 0.2
6-Galangin 16.1 ± 0.6 15.9 ± 0.5 12.0 ± 1.0
Sum of percentages 46.7 46.9 45.4
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Table 5. Analysis of Variance: contribution of geographical origin (country) on the relative percentage
(% w/w) of each main flavonoid species: flavonols (galangin, quercetin), flavones (chrysin, apigenin),
and flavonones (pinocembrin, pinobanksin).
Comparisons Significance
Quercetin Pinobanksin Apigenin Chrysin Pinocembrin Galangin
EU 1 vs EU 2 Yes * No ** No No Yes No
EU 1 vs EU 3 Yes No No Yes No No
EU 1 vs AM 1 Yes No No Yes Yes Yes
EU 1 vs AM 2 Yes No No No No No
EU 1 vs AM 3 No No Yes Yes Yes Yes
EU 1 vs AS 1 Yes No No Yes No Yes
EU 1 vs AS 2 Yes No No Yes No Yes
EU 1 vs AS 3 No Yes No No No No
EU 2 vs EU 3 No No No No Yes No
EU 2 vs AM 1 No No No Yes No Yes
EU 2 vs AM 2 No No No No Yes No
EU 2 vs AM 3 No No Yes Yes Yes Yes
EU 2 vs AS 1 No No Yes No Yes Yes
EU 2 vs AS 2 No No Yes No Yes Yes
EU 2 vs AS 3 No Yes No No Yes No
EU 3 vs AM 1 No No No Yes Yes Yes
EU 3 vs AM 2 No No No No Yes No
EU 3 vs AM 3 No No Yes Yes Yes Yes
EU 3 vs AS 1 No No Yes No No Yes
EU 3 vs AS 2 No No No No No Yes
EU 3 vs AS 3 No Yes No Yes Yes No
AM 1 vs AM 2 No No No Yes Yes Yes
AM 1 vs AM 3 No No Yes No Yes Yes
AM 1 vs AS 1 No No No Yes Yes No
AM 1 vs AS 2 No No No Yes Yes No
AM 1 vs AS 3 No Yes No Yes Yes Yes
AM 2 vs AM 3 No No Yes Yes Yes Yes
AM 2 vs AS 1 No No Yes No No Yes
AM 2 vs AS 2 No No Yes No No Yes
AM 2 vs AS 3 No Yes No No No No
AM 3 vs AS 1 No No Yes No Yes Yes
AM 3 vs AS 2 No No Yes No Yes Yes
AM 3 vs AS 3 No Yes Yes Yes Yes Yes
AS 1 vs AS 2 No No No No No No
AS 1 vs AS 3 No Yes Yes Yes No Yes
AS 2 vs AS 3 No Yes No Yes No Yes
* Yes means statistically significant difference between the relative percentage (% w/w) of each flavonoid in
hydroalcoholic propolis extracts from different origins. ** No means no statistically significant difference between
the relative percentage (% w/w) of each flavonoid in hydroalcoholic propolis extracts from different origins.
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Figure 1. Analysis of Variance: contribution of geographical origin (country) on the relative percentage
(% w/w) of each main flavonoid species: flavonols (galangin, quercetin), flavones (chrysin, apigenin),
and flavonones (pinocembrin, pinobanksin).
3.2. RP-HPLC–PDA–ESI–MSn Analyses of Non-Ethanolic M.E.D. Propolis
Raw propolis materials obtained from European (Eu1, Eu2, Eu3), Southern American (Am1,
Am2, Am3), and Asian regions (As1, As2, As3) were combined to obtain three mixtures of European,
American, and Asian poplar-type propolis (Eu + Am + As). Each mixture was submitted to the M.E.D.
extraction process to give the extracts A, B, and C, respectively.
After the identification of quercetin, apigenin, pinobaskin, chrysin, pinocembrin, and galangin
on the basis of their UV and mass spectra (Table 3 and Figure 3D), they were quantified by means
of HPLC–UV analyses (Table 6). The chromatograms acquired at λ 260 nm for each M.E.D. propolis
extract are reported in Figure 3A–C. The relative percentages of each flavonoid were tested with
ANOVA, showing that no differences were found in flavonoid composition between the non-ethanolic
M.E.D. propolis extracts (Figure 2).
Table 6. Relative percentage (% w/w) of the specific polyphenols occurring in the three propolis extracts
determined by high-performance liquid chromatography–UV (HPLC–UV).
Polyphenols M.E.D. Propolis A M.E.D. Propolis B M.E.D. Propolis C
1-Quercetin 1.1 ± 0.05 1.2 ± 0.10 0.9 ± 0.06
2-Pinobanksin 1.2 ± 0.40 0.8 ± 0.11 1.6 ± 0.36
3-Apigenin 1.2 ± 0.30 1.0 ± 0.20 1.4 ± 0.04
4-Chrysin 23.2 ± 0.60 22.0 ± 0.71 22.0 ± 1.02
5-Pinocembrin 1.17 ± 0.04 1.4 ± 0.06 1.4 ± 0.04
6-Galangin 13.4 ± 0.15 14.7 ± 0.11 14.3 ± 0.10
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Figure 3. Chromatograms registered at λ 260 nm. (A) Multi dynamic extraction (M.E.D.) propolis
extract A; (B) M.E.D. propolis extract B; (C) M.E.D. propolis extract C; (D) Standard compounds:
1—quercetin; 2—pinobainskin; 3—apigenin; 4—chrysin; 5—pinocembrin; 6—galangin.
3.3. Antimicrobial Activity of M.E.D. Propolis Extracts
The antimicrobial activity of the three M.E.D. propolis extracts was first tested against microorganism
strains representing the major families: Gram-positive or Gram-negative bacteria and fungi.
As expected, MIC values showed that the three M.E.D. pr polis extracts exerted antimicrobial
activity, confirming literature data on this property of propolis [18,19]. In particular, low MIC values
(ranging between 20 and 156 µg/mL) were found against Aspergillus niger, Streptococcus pneumonia
penicillin-susceptible, Moraxella catarrhalis, Atopobium vaginae, and Neisseria gonorrhoeae. Moderate
activity was found against Staphylococcus spp and Gardnerella vaginalis, (MIC value = 312 µg/mL). Poor
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effects were registered on the growth of Candida spp and Clostridium spp, shown by MIC values above
1250 µg/mL. No activity could be detected against Bacteroides fragilis and Lactobacillus spp (Table 7).
The results obtained by our experiments gave comparable MIC values for each extract obtained
using the M.E.D. method against the same microorganisms, despite the different geographical origins
of the three samples.
Table 7. Minimum inhibitory concentration (MIC) values of the M.E.D. propolis extracts A, B, and C against
the tested microbial strains, and of the antimicrobial drugs against their susceptible microrganisms.
Microbial Strain
MIC (µg/mL) MIC (µg/mL)
CODE A B C Antimicrobial agent
Staphylococcus aureus MSSA ATCC25923 L1280 312 312 312 -
Staphylococcus epidermidis ATCC12228 L147 312 312 312 -
Escherichia coli hyperpermeable G1640 312 625 625 0.078, trimethroprim
Moraxella catarrhalis L3292 39 78 78 0.3, ampicillin
Streptococcus pneumoniae
penicillin-susceptible L44 20 39 39 2.0, ampicillin
Candida albicans ATCC24443 L4120 1250 1250 1250 0.75, fluconazole
Candida albicans ATCC90028 L3023 1250 2500 2500 1.0, fluconazole
Candida parapsilosis ATCC90018 L3022 2500 2500 2500 4.0, fluconazole
Candida kruzei L2280 2500 2500 2500 10.0, fluconazole
Aspergillus niger ATCC10535 L53 78 156 156 1000, fluconazole
Bacteroides fragilis ATCC25285 L1011 5000 >5000 >5000 6.0, cefoxitin
Propionebacterium acnes ATCC25746 L1016 >5000 >5000 >5000 1.8, clindamycin
Clostridium difficile L1365 2500 2500 2500 0.6, vancomycin
Clostridium difficile ATCC17858 L4013 5000 2500 2500 1.6, vancomycin
Atopobium vaginae ND736 156 156 156 0.478, ampicillin
Lactobacillus gasseri ND787 5000 >5000 >5000 0.25, ampicillin
Lactobacillus acidophilus ND786 >5000 >5000 >5000 1.0, clindamycin
Neisseria gonorrhoeae L1600 156 156 156 16.0, ampicillin
Neisseria gonorrhoeae L1601 156 78 78 -
Gardnerella vaginalis L1629 312 312 156 0.020 ampicillin
Gardnerella vaginalis L1630 312 312 312 -
Therefore, since the chemical composition and the antimicrobial activity values of the three M.E.D.
propolis extracts were found to be comparable, we randomly selected extract A to investigate the
antimicrobial activity more widely, including against antibiotic resistant microbial strains, as reported
in Table 8. In this case, MIC values confirmed the antimicrobial activity of the extract against certain
types of microorganisms, revealing the same effects of propolis on both sensitive and resistant species.
Table 8. MIC values of M.E.D. propolis extract A and antimicrobial drugs on a wider microbial set.
Microbial Strain CODE
Propolis
Extract A
MIC (µg/mL)
Antimicrobial Agent
MIC (µg/mL)
Escherichia coli L4242 312 0.12, ampicillin
Staphylococcus aureus GISA MSSA L3797 625 -
Staphylococcus aureus GISA MRSA L3798 312 -
Staphylococcus haemolyticus MRSA L1730 312 -
Staphylococcus hominis ATCC27844 L323 625 0.046, ampicillin
Staphylococcus capitis MRSA ND021008 156 -
Staphylococcus xylosus MRSA ND026108 625 -
Staphylococcus simulans ND029808 1250 -
Staphylococcus haemolyticus MRSA ND040809 625 -
Staphylococcus haemolyticus MRSA L1729 1250 -
Staphylococcus aureus Clinda-inducible erm(A)+ ND053410 625 64.0, ampicillin
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Table 8. Cont.
Microbial Strain CODE
Propolis
Extract A
MIC (µg/mL)
Antimicrobial Agent
MIC (µg/mL)
Staphylococcus aureus Community Acquired
USA300 MRSA ND054910 625 -
Staphylococcus aureus MRSA macrolide-resistant ND060411 625 -
Staphylococcus aureus MRSA L4064 625 -
Staphylococcus epidermidis teicoplanin-resistant ND042409 625 -
Staphylococcus epidermidis ND052110 312 -
Staphylococcus epidermidis ND051710 625 -
Streptococcus pneumonia
clindamycin/erythromycin resistant L1542 39 -
Streptococcus pneumonia
macrolide/erythromycin resistant L1402 39 -
Streptococcus pneumoniae penicillin-resistant L3917 20 -
Candida guillermondii ATCC 6260 L2065 2500 2.5, fluconazole
Candida parapsilosis ATCC22019 L4119 1250 4.0, fluconazole
Escherichia coli ATCC25922 L1281 5000 5.0, ampicillin
Escherichia coli L47 5000 0.12, ampicillin
Pseudomonas aeruginosa ATCC27853 L1367 5000 128.0, ampicillin
Acinetobacter baumannii L3030 5000 4.0, ciprofloxacin
Clostridium difficile L1366 5000 1.6, vancomycin
Atopobium vaginae ND737 156 0.478, ampicillin
Lactobacillus paracasei L1693 5000 0.12, penicillin
Lactobacillus plantarum L19 5000 0.5, amoxicillin
Neisseria gonorrhoeae L1599 156 16.0, ampicillin
Gardnerella vaginalis L1622 312 0.020, ampicillin
Listeria monocytogenes ATCC13932 L1450 1250 0.563, ampicillin
Bacillus cereus ATCC10702 L85 312 2.0, penicillin
Clostridium perfringens HSR L4053 5000 4.06, clindamycin
Clostridium perfringens ATCC13124 L3697 2500 0.188, clindamycin
4. Discussion
Three sets of three propolis samples from Europe, America, and Asia were analyzed for their
polyphenol chemical composition by means of RP-HPLC–PDA–ESI–MSn, and then each set was
combined to obtain three mixtures of propolis that were submitted to the M.E.D. extraction method.
The analysis of variance showed that the chemical compositions of M.E.D. propolis extracts were
similar, whereas those extracted from the single propolis raw materials showed different compositions.
The three M.E.D. propolis were found to be not only chemically but also biologically reproducible.
In fact, these showed comparable antimicrobial activity against tested bacteria and fungi. Although
the MIC values reported in the literature are dependent on many variables such as the geographical
origin of the propolis, its chemical composition, method of extraction, and type of antimicrobial
activity measured, many studies report major activity of propolis targeting Gram-positive bacteria.
Our investigation on poplar-type propolis yielded evidence of a lowest MIC against Gram-positive
bacteria, with good results against some Gram-negative bacteria and poor activities against fungi.
Our data are in line with literature data. In fact, Muliet al. [22] described similar antibacterial
activity of propolis extracts against Pseudomonas aeruginosa, Salmonella typhi, Escherichia coli, S. aureus,
and Bacillus subtilis, with propolis sourced from three regions of Kenya and propolis extracts obtained
using different concentrations of ethanol. In another study, C. albicans was found to be the most
resistant strain and S. aureus the most sensitive to a Portuguese propolis [23].
In a fairly recent work on the antimicrobial activity of propolis on S. aureus, evaluated through
the determination of the MIC, Pamplona-Zomenhan et al. (2011) [24] found some MIC values agreed
with the results reported in literature, while yet others differed [21,25–28]. These differences, certainly
due to the use of different extraction methods and to the variability of the bacterial strains, could also
be dependent on different propolis samples, underlining the difficulty in studying the properties of
propolis via extracts with a variable composition.
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With the commonly used extraction methods (i.e., hydroalcoholic extraction), propolis extracts
show poorly replicable chemical composition and biological properties due to the variability in the
raw material. Nevertheless, in view of the uses for propolis extracts in drugs, foods, and cosmetics,
it is important to have non-ethanolic propolis extracts with a standardized chemical composition and
the guarantee of final products with the same biological properties. In our study, we are the first to
report the antimicrobial activities of three mixtures of poplar-type propolis from different geographical
areas with the same polyphenol content, obtained using the M.E.D. method as described in the
paper by Zaccaria et al. [11]. The extracts show the presence of the main flavonoid species, flavonols
(galangin, quercetin), flavones (chrysin, apigenin), and flavonones (pinocembrin, pinobanksin), that can
be involved in different inhibitory mechanisms of microbial activity, such as inhibition of the mobility
of the bacteria or peptidoglycan synthesis [29,30], pinocembrin-mediated inhibition of quorum
sensing [31], and adhesion blocking by galangin [32]. Galangin and apigenin are present in M.E.D.
propolis extracts with a relative average percentage w/w of 14.15% and 1.19%, respectively. In the
literature, galangin showed a MIC = 32 µg/mL against different types of S. aureus (ATCC25293, N315,
and Mu50), significantly suppressing bacterial growth at concentrations of 4, 8, and 16 µg/mL [33].
In another paper, apigenin and galangin were investigated against sensitive and antibiotic resistant
strains of S. aureus, Enterococcus faecalis, Enterococcus faecium, E. coli, and P. aeruginosa. Galangin was
shown to have a MIC ranging from 25 to 50 µg/mL against six strains of S. aureus, but negligible activity
against other species, partially inhibiting the growth of all six enterococci. Apigenin only displayed
marginal activity against S. aureus and did not show any activity against enterocci [34]. Quercetin is
present in M.E.D. propolis extracts at an average percentage w/w of 1.11%. A recent study revealed
antibacterial activity against S. aureus, E. coli, P. vulgaris, Shigella, P. aeruginosa, and Lactobacillus casei
var. shirota. S. aureus and P. aeruginosa were inhibited, with an MIC value = 20 µg/mL, while moderate
activity was seen against E. coli and P. vulgaris (MIC = 30 µg/mL) and no activity against Shigella flexneri
and Lactobacillus casei with MIC > 300 µg/mL [35]. Other compounds, pynocembrin, and pinobanksin,
revealed weak antibacterial activities against Gram-positive and Gram-negative strains. Pynocembrin,
present at a 1.30% average percentage in M.E.D. propolis extract, did not inhibit the growth of
S. aureus, as described in a paper by Soromou et al. [36]. Pinobanskin (1.20% average percentage in
M.E.D. propolis extracts) showed MIC > 515 µg/mL against four strains of S. aureus, but no data were
reported against E. coli. [37]. Finally, chrysin showed MIC > 50 µg/mL against S. aureus ATCC25923
methicillin-sensitive, S. aureus ATCC43300 methicillin-resistant, and different strains of E. coli [38].
The comparison between MIC values reported in the literature for each flavonoid and the concentrations
of these compounds present in M.E.D. propolis extracts, suggests that the antimicrobial activity of
M.E.D. propolis is not purely due to these flavonoids, but is influenced in a more complex matrix
effect. With this view, previous papers have reported that the antimicrobial activity of propolis can be
ascribed to the synergistic effects of phenolics and flavonoids [14,39] and other compounds such as
diterpenic acids [40].
Our study also evidenced interesting activities of M.E.D. propolis extracts against antibiotic
resistant bacteria such as Streptococcus pneumoniae clindamycin/erythromycin resistant and to a lesser
extent against different strains of Staphylococcus. Antibiotic resistance is a serious and urgent problem
for public health. As published by the CDC web site, at least 2 million people are infected with
antibiotic-resistant bacteria each year in the U.S., and at least 23,000 people die as a result. Infections
caused by antibiotic-resistant microorganisms are very difficult to treat and, in most cases, require
hospitalization and expensive therapeutic alternatives. The Antibiotic Resistant Gene Database (ARDB)
evidences about 20,000 genes potentially able to mutate and acquire antibiotic resistance by multiple
mechanisms of action [41]. Our results are encouraging and useful for the development of new
antimicrobial agents in the near future, targeting multi-resistant bacteria strains in support of ongoing
therapies. Our results also encourage the design of new anti-infective biomaterials alternative to
antibiotic-loaded materials [42]. Since the 1990s, the search for biomaterials able to thwart bacterial
contamination and infection has been exponential in terms of surface modifications and coatings [43–45].
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Recently, this research has been focusing on making the material surfaces not only bactericidal but
also functionalized with other favorable properties [46,47]. It is expected that the new generation of
anti-infective biomaterials will be able to integrate with host tissues, exert anti-inflammatory activities,
and promote wound healing, in addition to counteracting bacterial colonization [48]. Propolis is
a bactericidal compound worthy of recognition as a candidate for preparing new anti-infective materials.
It meets the expectations and corresponds with the newly emerging concepts of biocompatibility, being
endowed with multifaceted therapeutic bioactivities, mainly attributable to its polyphenol content [1,5].
In a very recent study, cornstarch incorporated with propolis and hyaluronic acid was found to improve
wound dressing [49]. Films based on polysaccharides loaded with propolis and vitamin C have been
shown to be an effective bio-coating to accelerate the healing of diabetic wounds [50]. Polyvinyl
alcohol (PVA) hydrogels loaded with a Brazilian propolis have been shown to be effective in promoting
burn wound healing [51]. Recent advances in therapeutic strategies to control the immune response
to implants have highlighted the role of propolis in modulating the behavior of neutrophils and in
harmonizing the cellular responses to biomaterials. Indeed, propolis seems to be able to favor the
transition of macrophages from the M1 to M2 phenotype, extinguishing inflammation [51]. A safe and
long-term use of polymeric materials requires the application of anti-degrading agents with a wide
range of actions. Raw propolis originating from two geographic regions of Europe was used to protect
natural rubber materials from degradation by oxygen, ozone, and microorganisms [52]. The addition
of propolis to a rubber mixture made the material resistant to thermo-oxidative aging and ozone
and protected it from biodegradation [53]. As for the new and interesting field of nanomaterials,
chitosan–propolis nanoparticles, prepared using propolis from Asia, exhibited the abilities to alter the
zeta potential of S. epidermidis, inhibit biofilm formation by modulating gene expression, and synergize
with antibiotics [54]. Propolis/polyurethane composite nanofibers and electrospun materials have
been proposed for biomedical applications [55]. Propolis polyphenols, although beneficially bioactive
molecules, pose problems of low bioavailability, and thus may benefit from targeted nanodelivery
systems via nanocarriers [56]. In particular, permeation through the buccal mucosa appears to be
a promising approach to bypass liver metabolism and release propolis-based nano-formulations and
niosomes locally or systemically [57,58].
As far as the in vitro cytotoxicity, it has been reported in the literature that propolis extracts express
toxic effects on tumor cells (the half-maximal inhibitory concentration IC50 sometimes approaching
values as low as 2 µg/mL) and, to a lesser extent, even on normal cells (IC50: 58 µg/mL) [59,60]. In the
early stages of the study of new biomaterials, investigations are required to assess their cytocompatibility
under conditions close to the final clinical application. The propolis extracts here presented will be
used as nanostructured coatings or nanoformulated drugs. Nanocoatings and nanoformulations can
be expected to amplify the antibacterial properties while minimizing the side effects towards host cells.
In conclusion, this study suggests the use of a non-ethanolic mixture of poplar-type propolis with
a standardized polyphenol content obtained by an extraction method such as M.E.D., so as to produce
comparable activity data. Moreover, the analysis of the antimicrobial data suggests new potential
medical applications for M.E.D. poplar-type propolis against antibiotic resistant microbial strains that
will need to be further investigated in the future.
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